Admin Control Panel

New Post | Settings | Change Layout | Edit HTML | Edit posts | Sign Out


March20 podcast Dr Hazen
anti-TMA pill in a year or 2 ? (scroll 12 mins)

Additional info:
MEBO Karen
at UK Findacure conf 2020

Scroll down and select country

MEBO Map Testing & Meetups

Full details :
want listed ? contact

MEBO - UBIOME study 2018



MEBO Gut Microbiome Study
"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"
Funded by uBiome Research Grant

"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"

Dynamics of the Gut Microbiota in
Idiopathic Malodor Production

Started May 2018 - Ongoing

Current people sent kits : 100/100
3 kits per person


Participation info : LINK English

MEBO Private Facebook Group
to join : go to
or contact
Join/Watch the weekly
BO Sufferers Podcasts



TMAU Petition world
TMAU UK end total:262
TMAU UK ends 23/01/20
TMAU Petition USA end total 204
USA : Moveon open
TMAU (Dominican)
Metabolomic Profiling Study

Start : Aug 2016
Stage 1 : 27 Canadian volunteers to test
Latest click here (26 oct) :
17 samples returned

Note : Stage 1 is Canada only.
Return cut-off date : passed
Analysis can take 6/8 weeks
Analysis start in/before Nov
MEBO Research is a
NORD Member Organization
See RareConnect TMAU

Popular Posts (last 30 days)

Upcoming get-togethers

Let us know if you want a meetup listed
Follow MeBOResearch on Twitter

Blog Archive

MEBO Metabolic Malodor Survey (international) for Dr Hazen click here
click to Read more/less

survey for ANYONE who identifies with METABOLIC MALODOR

begun : Oct20
end : no ending for now

Regular readers will know that Dr Stan Hazen et al at Cleveland Clinic are developing a TMA-blocker pill, as they proposed in a 2011 paper that TMAO is a factor in CVD. Recently Dr Hazen and colleagues contacted MEBO as they have always thought they could also help with TMAU. This survey is to give them an idea of the 'state of the community'. It is a "version 1". They may not even look (though they have access permission), but it could be useful to give them an overview of the community

MEBO had a zoom call with Dr Hazen and his team in October. Another zoom call is planned when they have time

This is a GOOGLE FORMS survey

short url for survey :

current participants : 113 (update 18dec20)

Tuesday, January 31, 2017

Support the MEBO Mission : RESEARCH




You can be involved without leaving your home!

As a registered not-for-Profit company in England and Wales since 2009, and a registered Public Charity in the United States since 2010, MEBO has done its best to raise awareness by being a participant, one way or another, in most of the government and private entities that have published information of TMAU, such as,

1. Organization Member of NORD, National Organization of Rare Disorders in the United States

2. MEBO Research UK is an Organization Member of EURORDIS, The Voice of Rare Disease Patients in Europe

3. RARE CONNECT: Eurordis is an "Initiative Connecting Rare Disease Patients Globally". All sufferers around the world are welcome to join Trimethylaminuria Community of RareConnect. Some moderators of this site are MEBO Directors.

4. ORPHANET : MEBO Research, UK

Orphanet has a link to the UK Medical Research Council funded (£358,000 GBP, equivalent to 422K/Euros or 552K/USD) research project performed by Dr. Elizabeth Shephard for a "Therapy for the body and Breath malodour disorder Trimethylaminuria (TMAU).


If MEBO directors in the US and the UK have been able to accomplish all this and more in only 8 years, imagine how much we could accomplish if more sufferers participated on the Rare Disease Day projects and events.
In addition to providing sufferers with the opportunity to do the MEBO TMAU Urine Test, MEBO has also supported research projects, such as the pre-clinical drug development for TMAU performed by Dr. Elizabeth Shephard as indicated in the Research Councils UK website, noting that, "Patient group MEBO [will have access] to the benefits of this research. (Click on the "Outcome" tab).

As promised in the MEBO Mission Statement, MEBO is not only focused on TMAU research and treatment, but is also very committed to the pursuit of research to identify other forms of odor conditions. Therefore, the MEBO Metabolomic Profiling Pilot Study was launched in Edmonton, Canada with Dr. David Wishart (PhD Yale, 1991) at the Wishart Lab, University of Alberta. It is a registered research project with the, Trial NCT02683876. (See updates.)

Click to see Info Pack
If MEBO directors in the US and the UK have been able to accomplish all this and more in only 8 years, imagine how much we could accomplish if more sufferers participated on the Rare Disease Day projects and events. Please refer to the,

Rare Disease Day
Patient Involvement : Research
28 February 2017.


María de la Torre
Founder and Executive Director

A Public Charity
MEBO's Blog (English)
El Blog de MEBO (español)
MEBO Brasil - Blog (Portuguese)


Post a Comment